Observation, Not Radiotherapy, After Radical Prostatectomy Observation, Not Radiotherapy, After Radical Prostatectomy
The investigators observed no benefit to adjuvant radiotherapy after radical prostatectomy in patients with prostate cancer in the phase 3 RADICALS-RT trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Active Surveillance Preferred in Low-Risk Prostate Cancer Active Surveillance Preferred in Low-Risk Prostate Cancer
When informed about treatment options, most men with low-risk prostate cancer chose active surveillance instead of active therapy in a recent Italy-based analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Soho House founder Nick Jones feared prostate cancer would kill him as he reveals only wife Kirsty Young knew the truth about his secret battle to live
Nick Jones, who set up the exclusive members club on London's Greek Street in 1995, was diagnosed with cancer in June 2022. He has since made a recovery. (Source: the Mail online | Health)
Source: the Mail online | Health - October 20, 2023 Category: Consumer Health News Source Type: news

Mays Cancer Center: Targeting certain molecular interactions could yield new strategies for treating prostate cancer
Molecular activity of androgen receptors could hold key to new therapeutic approaches to prostate cancer, according to research led by Mays Cancer Center of The University of Texas Health Science Center at San Antonio. SAN ANTONIO, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Research led by Mays... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 20, 2023 Category: Pharmaceuticals Tags: SVY Source Type: news

Prostate cancer symptoms explained - three questions could help diagnose you in 30 seconds
Prostate cancer is the leading cancer diagnosis among men in the UK, which kills a man every 45 minutes. Could you have a growing tumour inside of you? (Source: Daily Express - Health)
Source: Daily Express - Health - October 20, 2023 Category: Consumer Health News Source Type: news

2008 to 2020 Saw Increase in Survival for Advanced Prostate Cancer
THURSDAY, Oct. 19, 2023 -- During a time period with improvements in treatment of advanced prostate cancer, there was a simultaneous clinically meaningful increase in mean survival for men with de novo metastatic castration-sensitive prostate cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 19, 2023 Category: Pharmaceuticals Source Type: news

Enzalutamide + Leuprolide Top for Mets-Free Survival in Prostate Cancer
WEDNESDAY, Oct. 18, 2023 -- For patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide is best for metastasis-free survival, according to a study published in the Oct. 19 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 18, 2023 Category: Pharmaceuticals Source Type: news

Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train?
(MedPage Today) -- Come December, as I observe my "pros-mitzvah" -- 13 years on active surveillance (AS) for very low-risk prostate cancer -- I feel I'm at a tipping point. Should I stay the course and keep monitoring my lesion -- a single... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 18, 2023 Category: Hematology Source Type: news

Hope for thousands of men battling prostate cancer as scientists discover 'practice changing' drug combination that slashes risk of disease returning by 60%
Patients with prostate cancer who were given enzalutamide alongside the standard hormone treatment cut their chances of dying by 58 per cent, found researchers based in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - October 18, 2023 Category: Consumer Health News Source Type: news

How AI Can Make Cancer Treatment More Equitable
Many are aware of the Cancer Moonshot—an ambitious and hopeful initiative of the U.S. government to reduce cancer-related death rates by 50% by the year 2047. It will take an army to achieve this goal, composed of the brightest minds and biggest hearts in healthcare, science, and technology. Many parties will be involved—the federal government, healthcare providers, researchers, patients, caregivers, and advocates, among others in both the public and private sectors. One of the most pivotal tools that can help propel us toward this lofty goal is artificial intelligence (AI), which is poised to revolutionize can...
Source: TIME: Health - October 18, 2023 Category: Consumer Health News Authors: Andre Esteva Tags: Uncategorized Innovation Source Type: news

J & J ’s Medical Device Sales Feel the Side Effects of Weight-Loss Drugs
Riding high, Johnson & Johnson reported pharmaceutical sales worth $13.89 billion on Tuesday (Oct 17), a year-over-year growth exceeding 5%. The pharmaceuticals driving its growth are Darzalex, a biologic used for multiple myeloma, and Erleada, a prostate cancer treatment, in addition to several…#johnsonjohnson #darzalex #erleada #imbruvica #abiomed #altopharmacy #teamcubancard #medtechdivision #obese #glp1 (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2023 Category: Consumer Health News Source Type: news

Is Short-Term ADT Good Enough in High-Risk Prostate Cancer? Is Short-Term ADT Good Enough in High-Risk Prostate Cancer?
Continuing ADT beyond 6 months does not improve outcomes in men with high-risk localized prostate cancer also receiving brachytherapy and external beam radiation therapy, new research suggests.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Prostate cancer breakthrough as drug resistance reversed by stopping ‘hijacking’ of cells
Study lead Professor Johann De Bono said: "This is tremendously exciting - and it suggests we have an entirely new way to treat prostate cancer on the horizon." (Source: Daily Express - Health)
Source: Daily Express - Health - October 16, 2023 Category: Consumer Health News Source Type: news

These Factors Predict Shorter Time to PSA Failure These Factors Predict Shorter Time to PSA Failure
A new study identifies three factors associated with PSA failure in men with nonmetastatic unfavorable-risk prostate cancer, revealing who may benefit from treatment escalation.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 16, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hope for thousands of men battling prostate cancer after 'tremendously exciting' discovery of drug that can shrink tumours and extend lives
Scientists from London's Institute of Cancer Research say the experimental drug can shrink some prostate cancer tumours by 30 per cent. It may also be able to stop cancer in its tracks. (Source: the Mail online | Health)
Source: the Mail online | Health - October 16, 2023 Category: Consumer Health News Source Type: news